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Background. Two etiologic pathways of vulvar cancer are known, a human papillomavirus (HPV)- and a TP53-
associated route, respectively, but other genetic changes may also play a role. Studies on somatic mutations in
vulvar cancer other than TP53 are limited in number and size. In this study, we investigated the prevalence of
genetic mutations in 107 vulvar squamous cell carcinomas (VSCCs).
Methods. A total of 107 parafﬁn-embedded tissue samples of primarily surgically treated VSCCs were tested
for HPV infection and screened for mutations in 14 genes (BRAF, CDKN2A(p16), CTNNB1, FBXW7, FGFR2, FGFR3,
FOXL2, HRAS, KRAS, NRAS, PIK3CA, PPP2R1A, PTEN, and TP53) using Sanger sequencing and mass spectrometry.
Results.Mutations were detected in 7 genes. Of 107 VSCCs, 66 tumors (62%) contained at least one mutation
(TP53 = 58, CDKN2A(p16) = 14, HRAS = 10, PIK3CA = 7, PPP2R1A = 3, KRAS = 1, PTEN = 1). Mutations
occurred most frequently in HPV-negative samples. Five-year survival was signiﬁcantly worse for patients
with a mutation (47% vs 59%, P= .035), with a large effect from patients carrying HRAS-mutations.Conclusion. Somatic mutations were detected in 62% of VSCCs. As expected, HPV infection and TP53-
mutations play a key role in the development of VSCC, but CDKN2A(p16), HRAS, and PIK3CA-mutations were
also frequently seen in HPV-negative patients. Patients with somatic mutations, especially HRAS-mutations,
have a signiﬁcantly worse prognosis than patients lacking these changes, which could be of importance for the
development of targeted therapy.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Vulvar cancer is the fourth most common gynecological malignancy
with an incidence of 2 per 100,000 women each year in developed
countries [1]. This cancer is usually seen in post-menopausal women;
the average age at diagnosis is 70 years [2]. Although most patients
can be treated curatively by radical local excision, this surgical therapyRoom P1-40, Leiden University
rlands. Fax: +31 71 5266952.
.
. This is an open access article undercan be verymutilating and results in highmorbidity rates [3–5]. Almost
90% of all vulvar carcinomas are squamous cell carcinomas (SCCs) [6],
which can be divided into two different etiological types [7]. The ﬁrst
type occurs mainly in younger patients and is clearly associated with
high-risk human papillomavirus (hrHPV) infection and the precursor
lesion usual vulvar intraepithelial neoplasia (uVIN) [8]. The second
type is typically seen in elderly patients and seems to develop indepen-
dently from HPV infection. The HPV-independent type of carcinoma is
associated with lichen sclerosis and mutations in the TP53 gene, but
its etiology is much less well understood than the HPV-positive type
[7,8].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
150 M.D. Trietsch et al. / Gynecologic Oncology 135 (2014) 149–155Studies on somaticmutations in vulvar cancer other than in the TP53
gene are limited in number and size. As shown in studies concerning
other types of cancer, information about the role of genetic mutations
may help us understand the processes underlying vulvar cancer. In ad-
dition, mutation proﬁling may guide targeted therapies in cancer
[9–12]. If mutational status has prognostic signiﬁcance, we might be
able to select those patients who need a more radical approach versus
those who can be spared the morbidity of extensive radical surgery or
additional radiotherapy and/or chemotherapy. Somatic mutations
have been studied extensively in other types of gynecological cancer
and in squamous cell carcinoma (SCC) of the skin [13]. Based on this
knowledge, we have selected the genes that are most frequently affect-
ed in gynecological cancer and SCC of the skin that could play a role in
the tumorigenesis of vulvar cancer [14]. In this study, we investigated
the prevalence of somatic mutations in 14 different genes in 107 vulvar
squamous cell carcinomas (VSCCs) and correlated these changes with
survival.
Methods
Patients
Clinical and follow-up data were retrieved from patient medical re-
cords and the cancer registration database for patients whowere surgi-
cally treated for primary VSCC between 2000 and 2009 in the Leiden
University Medical Center, Leiden, the Netherlands, a referral center
for gynecological cancers. Patients were excluded if they had received
chemotherapy or radiotherapy in the pelvic area before surgery. Tumors
from which only biopsies were taken were excluded from the series.
Tumor staging was performed according to the FIGO system; we used
the 1995 staging instead of the revised 2009 staging because of the ret-
rospective design of the study [15,16]. Follow-up ended in December
2012. Patient samples were handled according to the medical ethical
guidelines described in the Code of Conduct for Proper Secondary Use
of Human Tissue of the Dutch Federation of Biomedical Scientiﬁc Socie-
ties. (www.federa.org, an English translation of the Code can be found
here: http://www.federa.org/sites/default/ﬁles/digital_version_ﬁrst_
part_code_of_conduct_in_uk_2011_12092012.pdf). Patients received
information on the secondary use of tissue that is sampled for diagnostic
use. They can actively object to secondary use.
Therapy
Patients were generally treated according to Dutch national and in-
ternational vulvar cancer guidelines [3]. Patients with unifocal VSCC
with a diameter b4 cm without suspicious groin nodes were generally
treated with radical local excision (RLE) and a sentinel node procedure.
Sentinel node mapping was performed using Technetium-99 m
nanocolloid combined with patent blue [17]. Tumors with a diameter
exceeding 4 cm or multifocal tumors were generally treated with RLE
and unilateral or bilateral inguinofemoral lymphadenectomy. In pa-
tients with tumors in FIGO stage III or higher but with contraindications
for extensive surgery, such as high age and comorbidity, RLE was
performed without inguinofemoral lymphadenectomy, followed by
(chemo)radioation.
Immunohistochemistry
Sections of 4 μm thick were taken from formalin-ﬁxed, parafﬁn-
embedded (FFPE) tissue blocks from selected patients with primary
VSCC. Tissue sections were stained as described previously [18] using
primary antibodies for pankeratin AE1/AE3 (clone MAB3412, 1:2000,
Millipore, Billerica, Massachusetts, USA) for the selection of tumor
area and for PTEN (clone 6H2.1, 1:80, Dako, Glostrup, Denmark) to
additionally assess aberrant expression of the protein.PTEN protein expression scoring was performed blinded for clinical
data and for the results from the mutation analysis. PTEN expression
was scored as positive or negative, with adjacent normal epithelium
and stroma as an internal positive control. Tumors with areas of mark-
edly decreased or absent PTEN expression were considered to have
aberrant expression.
DNA isolation
The pankeratin-stained slides were used to select an area consisting
of at least 70% tumor cells. Three 0.6-mm diameter tissue cores of
variable length were taken from the selected area in the FFPE blocks.
DNA isolation was performed in an automated fashion as described
previously using the Tissue Preparation System (Siemens Healthcare
Diagnostics, Malvern, Pennsylvania, USA) [19]. DNA quality was tested
by multiplex quality PCR that ampliﬁed 150-, 255-, 343-, and 511-base
pair products that were visualized using 2% agarose gel electrophoresis
and scored for quality (scale, 0–4) (primer sequences available upon
request).
HPV analysis
DNA extracted from two 10-μmwhole tissue sections was used for
HPV type analysis. Sections of a parafﬁn block without tissue were cut
before and after each tumor sample to prevent contamination and
served as a negative control. All blank parafﬁn sections were negative
in the PCR analysis. The INNO-LiPA HPV Genotyping Extra Amp kit for
in vitro diagnostic use (Innogenetics, Gent, Belgium), a highly sensitive
hybridization assay, was used for HPV typing as described previously
[20]. This assay can detect oncogenic and common HPV types [20].
Mutation genotyping using MALDI-TOF mass spectrometry
Mutation genotyping was performed using the GynCarta 2.0 panel
[14], which contains several loci on 13 genes (BRAF, CDKN2A(p16),
CTNNB1, FBXW7, FGFR2, FGFR3, FOXL2, HRAS, KRAS, NRAS, PIK3CA,
PPP2R1A and PTEN), following the manufacturer's protocol as described
previously [21]. Brieﬂy, wild-type and mutant DNA was ampliﬁed by
multiplex PCR. Shrimp alkaline phosphatase treatment inactivated
surplus nucleotides. A primer extension reaction (iPLEX® Pro) was per-
formed with mass-modiﬁed terminator nucleotides, and the product
was spotted on a SpectroCHIP (Sequenom, Hamburg, Germany). The
distinct masses were determined with MALDI-TOF mass spectrometry.
All 107 tumor samples were genotyped and 11 (10%) samples were
assayed in duplicate. Non-template (N = 4) and wild-type leukocyte
DNA (N= 2) controls were included in each multiplex to obtain nega-
tive and wild-type MALDI-TOF spectra.
Analyzing TP53 mutations
For analysis of somatic mutations in the TP53 gene, DNA sequencing
was performed for exons 5–8. For each sample, 2 μL (5 ng/μL) DNAwas
added to a 23-μL PCR mix containing 12.5 μL SYBRgreen (Bio-Rad,
Hercules, Callifornia, USA), 0.6 μL (10 pg/μL) of each primer (sequences
are available upon request), and 9.9 μL demineralized water. Real-time
PCR was performed for 40 cycles using an annealing temperature of
60 °C. For each exon, onewild-type leukocytewas used as a quality con-
trol. All PCR productswere puriﬁed by a vacuumusingMinElute 96-well
plates from the PCR puriﬁcation kit (Qiagen, Hilden, Germany).
Sequencing was performed for both forward and reverse strands by
Macrogen Europe (Amsterdam, the Netherlands).
Data analysis
Data were analyzed with MassARRAY Typer Analyser software
(TYPER 4.0.22, Sequenom, Hamburg, Germany) and MutationSurveyor
Table 1
Characteristics of the patients with vulvar squamous cell carcinoma in this study.
Characteristic Value
Follow upa – mo (IQR) 38.0 (16.0–69.0)
Age at diagnosisb – year (SD) 70.1 (14.0)
Duration of symptomsa – mo (SD) 5.0 (2.0–18.5)
FIGO stage – n (%)
Stage 1 29 (27.1)
Stage 2 36 (33.6)
Stage 3 30 (28.0)
Stage 4 12 (12.0)
Treatment – n (%)
Radical vulvectomy 68 (63.6)
Radical local excision 39 (36.4)
Adjuvant radiotherapy 43 (40.2)
Adjuvant chemotherapy 1 (0.9)
HPV positive – n (%) 18 (16.8)
Lymph node metastases – n (%) 41 (38.3)
Unilateral 28 (26.2)
Bilateral 13 (12.1)
Extracapsular growth 17 (15.9)
Tumor sizeb – mm (SD) 32.1 (22.2)
Inﬁltration deptha – mm (IQR) 6.0 (4.0–11.0)
Vasoinvasion – n (%) 15 (14.0)
Lymfangioinvasion – n (%) 3 (2.8)
Perineural growth – n (%) 4 (3.7)
Positive resection margins – n (%) 21 (19.6)
Disease status – n (%)
Patients in complete remission 82 (76.6)
Local recurrence 22 (20.6)
Second primary tumour 9 (8.4)
Regional recurrence 9 (8.3)
Died 59 (55.1)
Disease speciﬁc death 28 (26.2)
Regional metastases 8 (7.5)
Distant metastases 24 (22.4)
5-year overall survival – % (SD) 50.1 (5.1)
5-year disease speciﬁc survival – % (SD) 67.8 (6.3)
5-year disease free survival – % (SD) 27.9 (5.0)
Abbreviations: N = number; mo = months.
a Median (interquartile range, IQR).
b Mean (standard deviation, SD).
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blinded to tumor identiﬁcation inspected the cluster plots andmutation
calls to discriminate true mutant calls from artifacts, and a consensus
determination was reached.
Statistical analysis
Statistical analyses were conducted using the Predictive Analytics
Software package (version 17, IBM-SPSS Statistics, Armonk, New York,
USA). The independent t-test was used to compare baseline variables
and Fisher's exact test to analyze categorical and normally distributed
numerical data. We chose to also compare the separate characteristics
that make up the FIGO staging, because these characteristics are unaf-
fected by differences between the old and new FIGO staging systems.
The Shapiro–Wilk test was used to test for normality, and for data
with a skewed distribution, the Mann–Whitney U test was used.
Kaplan–Meier, the log-rank test, and Cox proportional hazard regres-
sion analysis including age, HPV infection, tumor size, and the most
frequent mutations in this cohort were performed to analyze differ-
ences in survival between groups of patients with and without genetic
mutations. A P value of .05 was considered signiﬁcant, corresponding
to 95% conﬁdence intervals (CIs). All tests were two-tailed. Results for
normally distributed numerical data are presented as the mean with
standard deviation (SD), and results for skewed numerical data are
presented as the median with interquartile range.
Disease-free survival was deﬁned as survival from the date of
surgery until the ﬁrst recurrence or death or until the end of study
follow-up. The overall survival of the patients was measured from sur-
gery until death from any cause or end of study follow-up, and
disease-speciﬁc survival was measured from the date of surgery until
death from vulvar cancer or the end of study follow-up. Recurrent dis-
ease in the vulvar area was characterized as ‘local recurrence’ whereas
a recurrence in the inguinal region was characterized as ‘regional
recurrence’. Recurrent disease on the contralateral side of the vulva
was considered to be a second primary tumor. Remaining recurrences
were documented as distant recurrences.
Results
Between January 2000 andDecember 2009, 129 patientswere surgi-
cally treated for primary VSCC at the Leiden University Medical Center.
Nine patients were excluded because they had a history of chemother-
apy, pelvic radiotherapy, or immunosuppressive therapy for vulvar can-
cer or any other disease prior to the current diagnosis. Eleven patients
were excluded because only a biopsy of their tumor was taken and no
further surgical treatment was given. Tumor tissue from one patient
was of poor quality and was not analyzed further. Thus, a total of 108
patients with surgically treated primary VSCC met all of our inclusion
criteria. This cohort of patients has been described before [22].
Of 108 samples, one was of such low DNA quality that it failed in all
tests, and we excluded this patient from further analyses. Table 1 lists
the characteristics for the included patients.
Of 107 samples, 18 (17%) were positive for hrHPV and 66 (62%)
carried at least one mutation. Of these patients, 16 (15%) had 2, and 7
(6.5%) had 3 different mutations. Fifty-eight (54%) patients harbored a
mutation on TP53. Sequencing for TP53 repeatedly failed for ﬁve pa-
tients. Fourteen patients carried a CDKN2A(p16) mutation, 10 an HRAS
mutation, PIK3CAwas found in 7 patients, mutated PPP2R1Awas identi-
ﬁed in three samples, and KRAS and PTENwere eachmutated in one pa-
tient. The most frequent combination of mutations was TP53 and
CDKN2A (11 patients, 10.3%), followed by TP53 and HRAS (7 patients,
6.5%). Additional immunohistochemistry revealed aberrant PTEN ex-
pression in another ﬁve samples. Fig. 1 provides a graphic representa-
tion of the mutation spectrum. Supplemental Table 1 lists the amino
acid and base pair changes for each patient. Of the 18 patients thattested positive for high-risk HPV, three also had a somatic mutation
(all TP53, Table 2).
Correlating clinical data with mutation status
A comparison between patients with a mutation in one of the tested
genes compared to those without mutations was made (Table 3).
Patients with at least one mutation in their tumor sample were signiﬁ-
cantly older (73 vs 65 years, P= .002) and had larger tumors (36 mm
vs 26 mm, P= .024) with deeper inﬁltration of the tumor (7.5 mm vs
5.0mm, P= .003). Tumor size was correlated with depth of inﬁltration
(Pearson Correlation .595, P b .001). Not having an HPV infection was
clearly associated with the detection of somatic mutations: Of the 18
HPV-infected patients, only 3 (4.5%) had a somatic mutation (all TP53)
whereas in non-HPV-infected patients, 63 out of 89 carried a mutation
(70.8%, P b .001)
Survival analysis
Patients carrying at least one mutation had a signiﬁcantly worse
overall 5-year survival (46.9% vs 58.9%, log-rank P = .035). Disease-
speciﬁc 5-year survivalwas 67.8% in patients carrying amutation versus
80.4% in patients without mutations (log rank P = .058) (Fig. 2).
Disease-free survival was comparable for patients with and without
mutations (37.8% vs 43.6%, log rank P= .472). Cox regression analysis
for disease speciﬁc survival including age, HPV infection, tumor size,
and the three most frequent mutations in this cohort (TP53, CDKN2A,
Fig. 1.Mutation spectrum. Mutation spectrum for 107 VSCC patients. Medium grey = wild type or non-infected. Dark grey = mutated or infected. Lightest grey = assay failed.
152 M.D. Trietsch et al. / Gynecologic Oncology 135 (2014) 149–155andHRAS), showed a signiﬁcantlyworse prognosis for patients carrying
anHRASmutation (hazard ratio 2.9, 95% CI 1.112–7.425). HPV infection
and CDKN2A or TP53mutations were not independent prognostic fac-
tors (Table 4). Interestingly, although the absolute number of coexisting
mutations did not correlate with an increased hazard ratio for disease-
speciﬁc death, having both an HRAS and a TP53 mutation or both a
CDKN2A and a TP53 mutation increased the hazard ratios to 5.1 (95%
CI 1.504–17.062) and 4.1 (95% CI 1.2–14.074), respectively, when
correcting for HPV infection, tumor size, and age.Discussion
The present results conﬁrm the hypothesis that HPV infection and
TP53mutations play a key role in the development of VSCCs. In agree-
ment with current understanding of the pathogenesis of vulvar cancer
[23], the two pathways (HPV and non-HPV related) could clearly be dis-
tinguished in this cohort. While patients infected with high-risk HPV
were signiﬁcantly less likely to carry somatic mutations, mutations
were not exclusively found in HPV-negative patients. Our results show
that not only TP53 plays a major role in HPV-negative VSCC patients
but that HRAS, CDKN2A(p16), and to a lesser extent PIK3CA are also fre-
quently mutated. A mutation in VSCC in CDKN2A has been described
previously [24], but the ﬁnding of mutations in HRAS, PIK3CA, CTNNB1,
PPP2R1A1, and KRAS has, to our knowledge, not been reported before
in vulvar cancer.
Following the currently accepted two-pathway etiology of VSCC,
vulvar carcinogenesis is either driven by a persistent HPV infection or
by a somatic mutation, most often in the TP53 gene. In contrast to this
hypothesis, in our analysis, we found a subgroup of patients (n = 26,Table 2
Somatic mutations detected in hrHPV positive and hrHPV negative patients.
Gene hrHPV negative hrHPV positive
n = 89 (83%) n = 18 (17%)
BRAF 0 (0) 0 (0)
CDKN2A 14 (16) 0 (0)
CTNNB1 0 (0) 0 (0)
HRAS 10 (11) 0 (0)
KRAS 1 (1) 0 (0)
NRAS 0 (0) 0 (0)
PIK3CA 7 (8) 0 (0)
PTEN 1 (1) 0 (0)
PPP2R1A 3 (3) 0 (0)
TP53 55 (62) 3 (17)
Abbreviations: hrHPV = high risk Human Papilloma Virus.25%) with neither any somatic mutation in our gene panel, nor an
HPV infection. As any other technique, sequencing and mass spectrom-
etry have their weaknesses. An asset of the mass spectrometry tech-
nique we have used is that it works well with low quality DNA, and
that it requires mutant allele proportions as low as 5%. Our tumor sam-
ples contained at least 70% tumor cells, so we have conﬁdence that the
mutations in our panel can be detected if present. We are aware of the
fact that these detection techniques have an acceptable, but no com-
plete coverage of the genes we have studied. We therefore expect that
the actual number of somatic mutations in VSCC might be slightly
higher thanwe have detected, and that a part of the 26 patients without
mutations or HPV, actually do carry a somatic mutation that we cannot
pick up using our panel. Sequencing the full length of all the genes we
have selected in this studywould be very interesting, but would also re-
quire large amounts of high quality DNA. Unfortunately however, FFPE
material is often of limited quantity and quality and therefore full se-
quencing is not possible.
One study [25] found that ﬁve out of eight patients (63%) in their
study harbored PTENmutations. Using hot-spotmutation analysis cover-
ing the same mutations that Holway et al. found, we detected no more
than one mutation in PTEN. This divergence could partially be explained
by the fact that the panel we used can detect only approximately 40% of
all known PTENmutations. We also applied immunohistochemistry to
complement the PTEN data but found no more than 5% of the tumors
showing loss of PTEN expression. Because PTEN is often downregulated
by epigenetic mechanisms rather than by somatic mutations alone, the
aberrant PTEN expression is likely not attributable to somatic mutations
in all ﬁve samples [26]. Our data thus suggest that the results by Holway
et al. might have given an overestimation of the prevalence of PTEN
mutations in VSCCs.
Our results could help clinicians in differentiating high-risk patients
with a worse prognosis who would beneﬁt from closer follow-up and
radical surgery or adjuvant treatment, from low-risk patients that can
be treated less aggressively with resulting less morbidity. Furthermore,
clinical trials have shown promising outcomes of targeted therapies,
such as in targeting the PI3K/AKT/mTOR pathway in colorectal cancer
[10]. The ﬁnding thatHRAS, and to a lesser extent PIK3CA, are frequently
mutated in vulvar cancer could be of great importance in the develop-
ment of new treatment strategies, and individualized treatment. Our
study revealed RAS mutations in 11 out of 107 patients (10 HRAS, 1
KRAS). Seven of our patients were found to have amutation in the onco-
gene PIK3CA, which is a downstream effector of the RAS pathway.
Monotherapy of PI3K inhibitors has demonstrated poor clinical efﬁcacy,
likely due to adaptive resistance of the tumor cells [27]. It seems that a
dual blockade of upstream RAS by MEK inhibitors, and a more down-
stream inhibition of PI3K, may have better clinical results than single
pathway blocking treatment [28]. Although a simultaneous mutation
Table 3
Comparison of the clinical outcomes for patients with and without somatic mutations.
Outcome 1 ≥ mutation No mutation P value
n = 66 (62%) n = 41 (38%)
Follow-upa – mo 34.5 (11.0–64.3) 55.0 (25.0–80.0) 0.043b
Age at diagnosisc – year 73.4 (11.9) 64.9 (15.6) 0.002b
Duration of symptomsa – mo 4.0 (2.0–18.5) 6.0 (2.5–19.0) 0.068
FIGO stage – n (%) 0.051
Stage 1 12 (18.2) 17 (41.5)
Stage 2 23 (34.8) 13 (31.7)
Stage 3 22 (33.3) 8 (19.5)
Stage 4 9 (13.6) 3 (7.3)
Treatment – n (%)
Radical vulvectomy 45 (68.1) 23 (56.1) 0.245
Radical local excision 21 (31.8) 18 (43.9)
Adjuvant radiotherapy 30 (45.5) 13 (31.7) 0.222
Adjuvant chemotherapy 1 (1.5) (0.0)
HPV positive – n (%) 3 (4.5) 15 (36.6) b0.001b
Lymph node metastases – n (%) 30 (45.5) 11 (26.8) 0.067
Unilateral 20 (30.3) 8 (19.5) 0.148
Bilateral 10 (15.2) 3 (7.3)
Extracapsular growth 14 (21.2) 3 (7.3) 0.063
Tumor sizec – mm 36.0 (22.8) 26.1 (20.1) 0.024b
Inﬁltration deptha – mm 7.5 (5.0–11.0) 5.0 (2.0–7.0) 0.003b
Vasoinvasion – n (%) 10 (15.2) 5 (12.2) 0.779
Lymfangioinvasion – n (%) 2 (3.0) 1 (2.4) 1.000
Perineural growth – n (%) 3 (4.5) 1 (2.4) 1.000
Positive resection margins – n (%) 15 (22.7) 6 (14.6) 0.453
Disease status – n (%)
Complete remission 46 (69.7) 36 (87.8) 0.036b
Local recurrence 14 (21.2) 8 (19.5) 1.000
Second primary tumour 7 (10.6) 2 (4.9) 0.544
Regional recurrence 2 (3.0) 2 (4.9) 0.877
Died 41 (62.1) 18 (43.9) 0.075
Disease speciﬁc death 21 (37.5) 7 (20.6) 0.106
Regional metastases 9 (13.6) 6 (14.6) 1.000
Distant metastases 16 (24.2) 8 (19.5) 0.639
5-year overall survival – % (SD) 46.9 (6.4) 58.9 (8.0) 0.035b
5-year disease speciﬁc survival – % (SD) 67.8 (6.0) 80.4 (6.7) 0.058
5-year disease free survival – % (SD) 37.8 (8.1) 43.6 (8.8) 0.472
Abbreviations: N = number; mo = months.
a Median (interquartile range, IQR).
b Signiﬁcant difference (P b .05).
c Mean (standard deviation, SD).
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both these patients and those with a single mutation in either of these
genes may beneﬁt from this dual targeted therapy. Research in other
tumor types has shown that also in PIK3CA wild type, KRAS mutated
colorectal cancers, a combination of PI3K/MEK inhibitors results in
greater tumor regression than treatment with one inhibitor alone [29].
These targeted therapies may be of special interest for the subgroup of
patients that currently cannot be treated by surgery alone or by surgeryFig. 2. Survival curves. Overall survival, P= .035 (left), and disease-speciﬁc survival, P= .058 (r
mutation detected; lower line (black) = mutation detected.at all, such as patients with inoperable distant metastasis and tumors
with spread into for example the rectum or bladder, or patients that
are unﬁt for surgery because of comorbidities or their high age.
Fourteen patients (13%) in our cohort tested positive for mutations
in CDKN2A. CDKN2A, encoding the proteins p16INK4A and p14ARF, is a
tumor suppressor gene that regulates the cell cycle by decelerating
cells progression fromG1 phase to S phase [30]. It functions as a stabiliz-
er of p53. TP53 is mutated in many different types of cancer andight) for 107 vulvar squamous cell carcinoma patients in this study. Upper line (grey)=no
Table 4
Cox regression analyses for disease speciﬁc survival.
Variable Hazard ratio 95% CI P value
Age (years) 0.980 0.948–1.013 .232
HPV infection b0.001 NA .963
Tumor size (mm) 1.022 1.006–1.039 .007
TP53 1.743 0.728–4.173 .212
CDKN2A 2.301 0.830–6.376 .109
HRAS 2.848 1.113–7.290 .029
CI = conﬁdence interval.
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cancerous cells, TP53 stops cells from dividing when aberrations in the
DNA are detected. Loss of normal p53 function leads to an uncontrolled
cell cycle and chromosomal instability [31]. Research in other types of
cancer such as head and neck SCC and breast cancer have reported a
correlation between TP53 mutations and a worse survival [32,33]. In
contrast, TP53 was not an independent prognostic factor in the multi-
variate survival analysis in our cohort. We found that patients with
TP53 mutations frequently carried additional mutations and that the
combination of amutation in both TP53 andHRAS or CDKN2A correlated
with a signiﬁcantly worse prognosis. When both CDKN2A and TP53 are
mutated, the cascade of destabilization of the tumor cells progresses,
and might indeed explain the worse survival of patients carrying both
mutations. The worse survival in patients carrying TP53 and HRAS is in
line with those of Zhang et al. who showed a markedly increased num-
ber of tumors and tumor size in transgenic mice with TP53 and HRAS
mutations [34]. The synergistic interaction and the resulting impair-
ment of prognosis could be explained by the roles that both genes
have in tumorigenesis.HRAS is a proto-oncogene, that, whenmutat-
ed, directs cell growth and division [28]. Since TP53 is a tumor
suppressor gene regulating cell cycle control, the combination of
these mutations set the stage for uncontrolled cell division. Another
explanation could be that TP53 mutated tumors are simply more
susceptible to additional mutations because of a lack of cell cycle
control. The reported worse prognosis in tumors with multiple mu-
tations could therefore also be a reﬂection of further progression of
the tumor.
The fact that additional mutations in CDKN2A and HRAS occur fre-
quently makes us question why there is a speciﬁc preference for these
two accessory mutations and whether TP53 mutations truly are the
drivers of aggressive tumor growth in VSCCs, or that this aggressiveness
is caused by the additional mutations that occur later on in tumor pro-
gression. A survival analysis stratiﬁed for different types of p53 protein
activity changes and gene location, and for the low frequent somatic
mutations that we found would be very interesting but requires study
cohorts much larger than the 107 we studied here. The same thing
applies to multivariate survival analyses: because of the relatively
small size of our cohort, it was not possible to correct for more possible
confounders thanwe already did. We therefore call for validation of our
results in larger or multiple cohorts. Because of the low prevalence of
VSCC, this can only be attained by multicenter and international
collaboration.Conclusion
Somaticmutations in TP53, CDKN2A(p16), andHRAS occur frequently
in HPV-negative VSCCs. Patients with a somatic mutation, and especially
thosewith amutation inHRAS, have a signiﬁcantlyworse prognosis than
patients without these changes.Conﬂict of interest statement
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